Read our editorial piece on page 48 in their June edition “Removing the Trial and Error Process from Depression”!
June 2019 //
Today, physicians are besieged with data. The Taliaz platform, PREDICTIX, changes this complex real-world patient data into physician-centric decision support tools.
Globally, depression is the leading cause of disability, with many patients experiencing a long and painful search for the right antidepressant. Patient dissatisfaction, poor treatment adherence and side effects can result from this. Artificial intelligence (AI) holds a lot of promise for changing this status quo. Using a deep understanding of scientific and neurological data, algorithms can be developed to analyze accumulating real-world datasets, such as from genomic banks and electronic health records.
Through identifying relevant genetic markers, highly complex prediction AI models can be built to personalize depression treatment. Founded by brothers Dekel and Oren Taliaz, this is exactly the neuroscientific, evidence-based approach used by the Tel Aviv-based startup, established in 2015, Taliaz.
Its AI prediction algorithm, PREDICTIX, is able to analyze hundreds of thousands of clinical, demographic, and genetic parameters involved in driving behavior, allowing it to optimize depression treatment. This technology platform is currently being tested in other psychiatric disorders, such as attention-deficit hyperactivity disorder. “Our goal is to use a scientific, critical and analytic approach to change how we think about treatment,” said Dekel Taliaz, CEO.
Personalizing antidepressant prescriptions with PREDICTIX.
Today, physicians are overwheled with data. The Taliaz platform, PREDICTIX, transforms this complex real-world patient data into physician-centric decision support tools.
As a result of collecting a patient’s DNA sample, along with their demographic and clinical history, PREDICTIX analyzes and provides a personalized prediction report for each patient. By providing information about antidepressant drugs and the types of treatment most appropriate for each patient’s genetic makeup and health record, the report empowers Physicians’ clinical decisions. Using data from the largest ever prospective study on depression therapies, the USA STAR*D Study, the PREDICTIX algorithm can accurately predict efficacy and side effects of current antidepressants with nearly 80% accuracy.
“PREDICTIX is about learning from the choices that are made to reduce the trial and error,” said Dekel Taliaz. “As physicians use PREDICTIX, our algorithms learn from these new datasets to further optimize our treatment predictions. We are then packaging this science for physicians and patients in an easy-to-use, noninvasive and straightforward way. It is hardcore science, but very practical.”
In March 2019, Taliaz launched the online, medically managed PREDICTIX service in the UK with the leading online psychiatry service, Psychiatry UK. PREDICTIX is also being implemented in France and in the Israeli health system, following an $8 million agreement with the Israel Ministry of Health.